Cancer cells that accumulate extra copies of their entire chromosome set can start behaving like immune cells, swallowing their neighbors and migrating through tissue to seed tumors in distant organs. That is the central finding of a growing body of peer-reviewed research, anchored by a 2025 paper in the Journal of Cell Biology from a team led by Yoichiro Tamori at Hiroshima University that traced the behavior to a specific stress-signaling pathway, and now supported by converging evidence from fruit fly models, human lung cancer lines, and patient chromosome records.
The condition at the center of this work is called polyploidy, a state in which a cell carries more than the normal two sets of chromosomes. Polyploidy has long been observed in aggressive tumors, but until recently, researchers lacked a clear mechanistic explanation for why these oversized cells tend to spread. The new evidence points to a surprisingly direct chain of events: surplus chromosomes force cells to produce more protein than their internal machinery can handle, generating reactive oxygen species that activate a signaling cascade known as JNK. Rather than triggering cell death, that stress response appears to unlock mobility and predatory behavior.
A stress pathway that rewires cell behavior
The most detailed experimental work comes from Tamori and colleagues at Hiroshima University, published in the Journal of Cell Biology. Using both Drosophila epithelial tissue and human lung cancer cells, the team showed that polyploid cells begin functioning as nonprofessional phagocytes. In plain terms, they start engulfing surrounding cells, a job normally reserved for macrophages and other immune cells. Tamori’s group tied this behavior directly to JNK signaling, which becomes activated when the cell’s protein-production system is overwhelmed by the extra genetic material.
“The polyploid cells acquired phagocytic activity through JNK-dependent oxidative stress,” the authors reported, describing a mechanism in which the sheer volume of surplus protein triggers a cascade that repurposes the cell’s cytoskeleton for engulfment rather than normal tissue maintenance.
Once JNK switches on, the downstream effects compound. The cell becomes more motile, more likely to consume neighboring cells, and better equipped to clear debris and invade tissue. These are hallmark traits of metastasis, the process by which cancer spreads from its original site to other parts of the body. The fact that the finding was reproduced across species, in both fly tissue and human cancer cells, reduces the likelihood that it reflects an artifact of a single experimental system.
A separate line of evidence reinforces the connection between abnormal chromosome counts and metastatic ability. A 2024 study by Yue Zhang, Uri Ben-David, and colleagues at Tel Aviv University, published in Nature Communications, demonstrated that aneuploid embryonic stem cells, isolated from circulating tumor populations, showed heightened migration and organ colonization in a teratoma model. Functional assays confirmed these cells were not merely surviving in the bloodstream but actively establishing new tumors in distant organs.
Earlier research comparing isogenic cell lines with different ploidy levels found that spontaneous chromosome duplication altered organ-specific metastasis patterns. Larger polyploid cells were more likely to lodge in organs with continuous vasculature, such as the lungs and brain, according to work published in Cell Research. The explanation is partly mechanical: bigger cells get physically trapped in narrow capillary beds, giving them more time and opportunity to invade surrounding tissue and establish secondary tumors.
The picture is not uniform, however. Studies on colon cancer cell lines have shown that specific chromosome gains can either promote or suppress invasiveness, depending on which chromosome is duplicated and which genes it carries. Polyploidy, in other words, is not a single switch that always drives cancer forward. Some extra chromosomes may restrain malignancy while others accelerate it, adding a layer of specificity that researchers are still working to map.
Independent experiments on stable tetraploid cancer cell clones, conducted prior to the Tamori group’s JCB paper, confirmed preferential migration and invasion in both laboratory assays and patient cytogenetic data drawn from the Mitelman Database, a comprehensive catalog of chromosome abnormalities in human cancers maintained by the U.S. National Cancer Institute. That convergence between controlled bench experiments and clinical records strengthens the case that polyploidy is not just a laboratory curiosity but a feature of real human tumors with measurable consequences.
What remains uncertain
Despite the accumulating evidence, several important gaps persist. No published clinical trial data yet link JNK inhibition to reduced metastasis in polyploid tumors. The therapeutic angle is biologically plausible, but blocking JNK safely in patients presents a distinct challenge: the pathway plays essential roles in normal wound healing, stress responses, and immune regulation. Shutting it down broadly could cause serious side effects.
For patients already living with advanced cancer, the research raises a pointed question: could the very treatments meant to shrink tumors be selecting for polyploid cells that are harder to kill and more prone to spread? Kenneth Pienta, a cancer researcher at Johns Hopkins University who has studied polyaneuploid cancer cells, has described these cells as a “protected state” that can weather chemotherapy and later regenerate the tumor. If that model holds broadly, it would mean that standard treatment regimens might inadvertently enrich the most dangerous subpopulation of cancer cells.
The prevalence of polyploidy across different human cancer types also lacks systematic documentation. The strongest experimental work to date focuses on lung cancer cells, colon cancer lines, and teratoma models. Whether the same JNK-driven mechanism operates in breast, pancreatic, or prostate cancers has not been directly tested with primary experimental data. The relationship between failed apoptosis checkpoints and polyploid cell emergence has been established as a general principle linking genome instability to cancer progression, but how much this varies by tissue type remains an open question.
How polyploid cells interact with the immune system is another poorly characterized area. The discovery that polyploid epithelial cells can perform phagocytosis raises an unsettling possibility: these cells might evade immune detection by mimicking immune cell behavior. No direct assays have tested this hypothesis in living organisms, but the gap matters enormously. Immune evasion is a central concern in designing immunotherapies, and if polyploidy helps cancer cells disguise themselves, it could be undermining treatments that depend on the immune system recognizing tumors as foreign.
The stability of polyploid states over time is also unclear. Some evidence suggests that polyploid cancer cells can undergo reductive divisions, shedding chromosomes to generate highly diverse offspring. If this is common in human tumors, polyploidy might function as a transient survival strategy that seeds genetic diversity rather than a permanent cellular identity. The distinction has practical implications: a stable polyploid population could potentially be targeted directly, while a transient one would require therapies designed to anticipate and block its downstream progeny.
Finally, researchers have not fully disentangled how much of the aggressive behavior stems from mechanical factors versus biochemical signaling. Larger cell size clearly affects how cells navigate blood vessels and tissues, but JNK activation and related stress responses also reprogram gene expression in ways that could be equally important. Separating physical constraints from signaling effects will require experiments that manipulate cell size and pathway activity independently, something that has been attempted only in limited ways so far.
Why polyploidy is reshaping how researchers model metastasis
The strongest claims in this field rest on controlled laboratory experiments: isogenic cell line comparisons, functional migration assays, and organ colonization tests in animal models. These represent primary evidence with defined endpoints and clear experimental controls. The JNK mechanism described by Tamori’s group carries particular weight because it was validated across species, in both fly tissue and human cancer cells, reducing the chance that the result is an artifact of any single model.
Patient cytogenetic data from the Mitelman Database adds clinical grounding but remains observational. It shows a correlation between tetraploidy and metastatic behavior in human cancers without proving causation on its own. Paired with the laboratory work, however, the combined evidence is considerably stronger than either line alone: mechanistic studies explain how polyploidy could drive metastasis, and human data show that tumors carrying these features are indeed more likely to spread.
The concept of polyaneuploid cancer cells, sometimes called PACCs, provides a framework for understanding why polyploidy matters beyond the laboratory. Research on PACCs has shown that these cells can survive harsh conditions, including chemotherapy, and later give rise to progeny with renewed capacity to grow and divide. In that model, polyploidy functions as a stress-resistant, slow-cycling state that allows cancer to outlast treatment and re-emerge in a more dangerous form. Combined with the newly described abilities to migrate, lodge in distant organs, and engulf neighboring cells, PACCs represent a plausible engine for both relapse and metastasis.
As of May 2026, the field is still filling in key gaps about tissue specificity, immune interactions, and therapeutic vulnerabilities. But the trajectory is clear: multiple independent research groups, working with different model systems and different cancer types, are converging on the same conclusion. Extra chromosomes do not just make cancer cells bigger. They make them more resourceful, more mobile, and harder to kill. Whether that understanding can be translated into treatments that specifically target polyploid cells is the question that will define the next phase of this research.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
